An artist who is driven by money is no longer driven by art"? Jason E. Hodges
Today, we look at a small healthcare concern in one of the most challenging parts of the biopharma space. This $3.50 antibiotic play signed a huge contract with BARDA in December which should derisk its prospects substantially and seems only partially priced into the stock. A full investment analysis is provided below.
Company Overview
Paratek Pharmaceuticals, Inc. (PRTK) is a Boston based commercial-stage biopharma concern focused on the development of antibiotics. It has two commercial stage